Historical record - last NADAC effective date: 2/22/2023
Product Information
QBREXZA 2.4% CLOTH is a brand product labeled by Journey Medical Corporation, priced at $20.5973 per EA under NDC 69489041130. Its NADAC has been published 68 times since Mar 16, 2022.
FDA first approved this application on Jun 28, 2018.
Strength
2.4 g/100g
Manufacturer
Journey Medical CorporationNDC
69489041130
Classification
Brand
Dosage Form
CLOTH
Route
TOPICAL
Effective Date
2/22/2023
Active Ingredients
GLYCOPYRRONIUM TOSYLATEApproval Type
New Drug (NDA)
FDA Application
NDA210361FDA Approved
6/28/2018
On Market Since
6/28/2018
Pharmacological Classes
Price Statistics
The NADAC for QBREXZA 2.4% CLOTH has been published 68 times since Mar 16, 2022, and over the history we have for it it has risen 6.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $20.5973 per EA |
|---|---|
| All-time high | $20.7176 (Feb 15, 2023) |
| All-time low | $19.3276 (Mar 16, 2022) |
| Median price | $20.7176 |
| Average price | $20.5491 |
| Largest weekly change | +6.5% (May 4, 2022) |
| Weeks tracked | 68 |
| Tracking since | Mar 16, 2022 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+6.6%
Last surveyed Jun 28, 2023 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the glycopyrronium market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Journey Medical Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
glycopyrronium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anticholinergic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QBREXZA 2.4% CLOTH?
The current National Average Drug Acquisition Cost (NADAC) for QBREXZA 2.4% CLOTH, manufactured by Journey Medical Corporation, is $20.5973 per EA (NDC 69489041130), effective Jun 28, 2023.
How has the price of QBREXZA 2.4% CLOTH changed over time?
Over the history we have for it, the NADAC for QBREXZA 2.4% CLOTH has risen 6.6%. It has been tracked across 68 weekly CMS publications since Mar 16, 2022.
What are the highest and lowest recorded NADAC prices for QBREXZA 2.4% CLOTH?
Since Mar 16, 2022, the NADAC for QBREXZA 2.4% CLOTH has ranged from a low of $19.3276 (Mar 16, 2022) to a high of $20.7176 (Feb 15, 2023), with a median of $20.7176 per EA.
Are there cheaper alternatives to QBREXZA 2.4% CLOTH?
No other NADAC-published product currently shares the active ingredient and strength of QBREXZA 2.4% CLOTH in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures QBREXZA 2.4% CLOTH?
QBREXZA 2.4% CLOTH (NDC 69489041130) is labeled by Journey Medical Corporation, and CMS classifies it as a brand product.